Trial Profile
A Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of Px-102 to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs PX 102 (Primary)
- Indications Metabolic syndrome; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Phenex Pharmaceuticals
- 08 Dec 2013 New trial record